StreetInsider.com News Articles

Piper Sandler Reiterates Overweight Rating on Viking Therapeutic (VKTX)

Tue, 07 Jul 2026 07:52:10 -0400

Piper Sandler analyst Biren Amin reiterated an Overweight rating and $71.00 price target on Viking Therapeutic (NASDAQ: VKTX).

The analyst commented: "Road Map of 3Q26 VK2735 SC Maintenance Data, An Under-the-Radar Catalyst; We view VKTX’s 3Q26 SC maintenance data as an underappreciated catalyst for VK2735 ahead of the Phase 3 VANQUISH readout expected in mid-to-late 2027. While the study is designed to test QOW/monthly maintenance dosing feasibility, we believe the 21-week induction period should be another key focus, as it represents the longest VK2735 exposure dataset to date and includes the first efficacy readout at doses above 15 mg. In our

Viking Therapeutic (VKTX) Reiterated at Overweight by Cantor Fitzgerald

Wed, 01 Jul 2026 07:03:07 -0400

Cantor Fitzgerald analyst Steven Seedhouse reiterated an Overweight rating and $100.00 price target on Viking Therapeutic (NASDAQ: VKTX).

The analyst commented, "In 3Q26, we expect Viking to report data from its ongoing Phase 1 subcutaneous "Maintenance Study" testing injectable GLP-1/GIP dual agonist VK2735 in various new dosing regimens including 1) different titration schema than prior studies or ongoing Phase 3 studies, 2) higher induction doses than previously studied, 3) weekly maintenance dosing after achieving significant weight loss, and 4) monthly maintenance dosing. The setup into the data is sneaky and likely very good so long as the Street is aware that

Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019

Wed, 24 Jun 2026 07:05:25 -0400

Viking Therapeutics, Inc. (NASDAQ: VKTX) has initiated a Phase 1 clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA) being evaluated as a potential weight loss treatment, according to a company statement.

The trial is a randomized, double-blind, placebo-controlled single ascending dose study enrolling healthy adults with a body mass index of 30 or above. Primary objectives include evaluating the safety, tolerability, and pharmacokinetics of single subcutaneous doses of VK3019. Exploratory assessments will also measure changes in body weight following a single dose. The study follows clearance of an investigational new drug application by the U.S. Food

Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019

Wed, 24 Jun 2026 07:05:25 -0400

Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019

Wed, 24 Jun 2026 07:05:25 -0400

Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019

Wed, 24 Jun 2026 07:05:25 -0400

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

SAN DIEGO, June 24, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today the initiation of a Phase 1 single ascending dose (SAD) clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA). VK3019 is being developed as a potential treatment option for weight loss. The study initiation follows the

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults

Wed, 24 Jun 2026 07:05:00 -0400

Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019

Potential to further expand Viking's treatment options for weight loss

Viking Therapeutics names Hubert Chen as chief medical officer

Thu, 11 Jun 2026 07:05:13 -0400